Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 18/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298928 | 0.87 | SORD (1.00) | SORD | |
| SCHEMBL6298975 | 0.87 | SORD (1.00) | SORD | |
| SCHEMBL6298953 | 0.85 | SORD (1.00) | SORD | |
| SCHEMBL6818853 | 0.85 | SORD (1.00) | SORD | |
| SCHEMBL6294558 | 0.85 | SORD (1.00) | SORD | |
| SCHEMBL7249196 | 0.85 | SORD (1.00) | SORD | |
| SCHEMBL6294633 | 0.85 | SORD (1.00) | SORD | |
| SCHEMBL6293142 | 0.85 | SORD (1.00) | SORD | |
| SCHEMBL6297795 | 0.85 | SORD (1.00) | SORD | |
| SCHEMBL6293404 | 0.85 | SORD (1.00) | SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337271-B1 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | claimed |
| US-6936600-B2 | Sorbitol dehrydrogenase inhibitors | PFIZER INC (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-6544998-B2 | For treatment of suffering from diabetic complications like diabetic neuropathy, nephropathy, cardiomyopathy, retinopathy, microangiopathy, macroangiopathy, cataracts and foot ulcers. | PFIZER INC | 2003-04-08 | — | — | US | disclosed |
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | MYLARI BANAVARA L (US) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SORD 2/4885 |
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | SORD, GABRE, SLC6A1 | SORD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.